FDA Waiting For EGFR Diagnostic Kit Data As Supplement To Vectibix BLA

In what could signal a trend for targeted therapies, FDA concluded in its review of Amgen's epidermal growth factor receptor inhibitor Vectibix that the diagnostic test kit used to screen subjects for EGFR expression would need to be submitted as a supplement to the BLA

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet